Clinical Trial Detail

NCT ID NCT03442556
Title Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements Yes
Sponsors University of Washington
Indications

prostate adenocarcinoma

Therapies

Carboplatin + Docetaxel + Rucaparib

Age Groups: adult senior

Additional content available in CKB BOOST